Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WellPoint

Executive Summary

Four drugs added to Blue Cross of California formulary, including Schering-Plough's Claritin, Knoll's Dilaudid, SmithKline Beecham's Paxil and Janssen's Propulsid. Blue Cross' newsletter to pharmacies notes that Paxil "should be reserved for patients who cannot tolerate the side effects or who do not respond to the tricyclic antidepressants." Propulsid "should be reserved for patients who have failed or cannot tolerate metoclopramide." The pharmacy benefits company is adding a pharmacy incentive, paying pharmacies "an annual bonus of $0.20 on each generic prescription dispensed if [their] generic substitution rate surpasses 79.99% of the available multi-source medications." An additional annual bonus of $0.30 will be paid for each drug dispensed that is listed on the Blue Cross of California formulary if the pharmacy's formulary dispensing rate is greater than 84.99%, the company says

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel